Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension of Luspatercept in Beta-Thalassemia
NCT02268409Phase 2Completed
- Start
- Oct 2014
- Primary completion
- Jun 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in beta thalassemia. Primary endpoints: Number of Participants Who Experienced an Adverse Event (AE) up to 68 months and Number of Participants Who Discontinued Study Treatment Due To an AE up to 60 months. Started Oct 2014; status: completed.
02
Drugs
luspatercept
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT02268409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268409.